TWITTER ANALYSIS

← Back to all analyses

Biological Risk

Weekly Week 9, 2026 Completed: Feb 27, 2026

Weekly biorisk summary — last week

  • Overall picture: Last week’s biorisk reporting was dominated by converging vaccine-prevention crises (large measles activity and falling childhood vaccination coverage), expanding H5N1 avian‑influenza detections across wildlife and commercial flocks (including the first California detections in northern elephant seals), a major food‑product linked infant botulism cluster, and notable clinical/regulatory developments (a negative phase‑3 mpox drug trial, scrutiny of preparedness funding and regulatory decisions). Below are the key themes, trends, data points, and the most significant events.

Key themes and topics

  • Measles: intense outbreak activity in multiple countries and U.S. jurisdictions, rising public‑health costs, and alarm over falling routine childhood vaccine uptake. See CIDRAP’s analysis on the economic impact of a 2025 measles resurgence (CIDRAP tweet).
  • Highly pathogenic avian influenza (H5Nx/HPAI): continued spread across poultry, wild birds, and spillover into mammals (including seals, felids, and other wildlife). New species detections and multiple commercial flock depopulations were reported. Example: first H5N1 cases in northern elephant seals in California (CIDRAP tweet).
  • Foodborne / product‑associated biorisk: a multistate infant botulism outbreak linked to powdered infant formula (ByHeart) prompted public‑health alerts and investigations (CIDRAP tweet).
  • Clinical trial / therapeutic news: a phase‑3 randomized trial found tecovirimat (Tpoxx) did not improve key clinical mpox outcomes versus placebo; results published/flagged by NEJM and media (NEJM tweet, CIDRAP tweet).
  • Vaccination policy, coverage and litigation: falling birth‑dose hepatitis B coverage and contentious policy moves triggered lawsuits and political scrutiny, with states suing over changes to federal childhood vaccine guidance and debate during Senate hearings about vaccinal schedule changes (CIDRAP vaccine‑coverage; 15 states suit; surgeon general nominee hearing).
  • Preparedness and governance: a GAO‑style concern surfaced about nearly $900M in HHS preparedness funds lacking coordinated oversight (CIDRAP tweet). Regulatory decision‑making at the FDA and leadership changes at CDC were also reported (e.g., a surprise FDA rare‑drug rejection and a CDC deputy resignation — STAT coverage) (statnews rejection; CDC resignation).

Notable patterns and trends

  • Off‑target impact of declining routine immunization: multiple items point to sustained drops in some routine vaccine rates (notably birth‑dose hepatitis B) and measurable consequences — increased outbreak size, higher economic cost estimates, and litigation and political response. The analysis linking vaccination declines to broad consequences was flagged by CIDRAP and Yale collaborators (CIDRAP thread).
  • HPAI geographic and host expansion: continued detection of H5Nx in commercial poultry, wild birds, and an expanding list of mammals (elephant seals, mountain lion, skunk). Reporting shows repeated U.S. commercial‑farm detections (PA, SD, IN, SC, etc.) plus international confirmations (Argentina, South Korea, Israel) — an ongoing multi‑sector animal health challenge with zoonotic concern (representative detection: USDA/FluTrackers reports, e.g. Lancaster, PA: https://x.com/FluTrackers/status/2027040096088698925; SD flock: https://x.com/FluTrackers/status/2027039675718975567).
  • Convergence of clinical evidence and policy friction: clinical trial data (negative tecovirimat mpox results) and vaccine‑policy disputes (legal challenges, Senate testimony) are adding friction to outbreak response messaging and clinical guidance.

Important mentions, interactions, and data points

  • Measles: CIDRAP estimated a $244M price tag for the 2025 measles resurgence, and reiterated that the measles vaccine prevented ~85,000 deaths in the U.S. between 1994–2023 (CIDRAP). Multiple local outbreaks noted: South Carolina cumulative 979 cases with Spartanburg county the epicenter (CIDRAP); Lancaster County, PA reported multiple cases this month (FluTrackers); DRC reported a massive rise in suspected measles (3,076 new suspected cases, 38 deaths in a recent report) (FluTrackers DRC). Several exposure alerts tied to travel hubs and public venues were reported (airports, churches, retail locations).
  • Hepatitis B birth‑dose decline: U.S. birth‑dose hepatitis B rates rose to ~84% in Feb 2023 then fell to ~73% by Aug 2025; the drop of >10 percentage points drew attention and policy debate (CIDRAP). The policy change by the Trump administration to reduce the childhood vaccine schedule prompted multi‑state legal action seeking nullification (CIDRAP lawsuit).
  • Mpox therapeutic trial: The STOMP/A5418 phase‑3 trial found tecovirimat did not meaningfully improve clinical resolution versus placebo at 29 days (83% vs 84% resolved), a high‑impact clinical result published by NEJM and summarized by CIDRAP (NEJM; CIDRAP).
  • Preparedness finance and governance: CIDRAP highlighted a review that ~ $900M in HHS preparedness funds lacked coordinated oversight, raising questions about the efficiency of national preparedness spending ahead of ongoing zoonotic threats (CIDRAP).
  • Science & surveillance items of note: Nipah F‑protein mapping for constrained epitope identification and vaccine immunogen design (jbloom_lab paper) — important for Nipah countermeasure R&D (jbloom_lab study). Antimicrobial resistance threatens long‑term declines in lower‑respiratory infection mortality per a new global analysis (CIDRAP antibiotic resistance piece).

Significant events (each summarized in a paragraph)

Measles resurgence, outbreak burden, and estimated economic cost

The outbreak wave and falling routine vaccine uptake drew sustained attention. CIDRAP published an analysis estimating a $244M cost associated with the 2025 measles resurgence and emphasized the long‑term mortality prevented by measles vaccination (an estimated 85,000 U.S. deaths averted between 1994–2023). Multiple jurisdictions reported outbreaks and exposure alerts (South Carolina: 979 cases with Spartanburg county an epicenter; international signals from DRC, Israel, New Zealand, Australia and other countries). The combination of sizable outbreaks, travel‑linked exposures, and declining birth‑dose/childhood vaccine coverage has generated litigation and political response (CIDRAP summary; SC outbreak; DRC surge).

H5N1 avian influenza: expanding host range and repeated commercial‑farm detections

HPAI activity continued across regions and species. Notably, California confirmed H5N1 in northern elephant seals — the first detection in that marine mammal in the state — underscoring cross‑species spillover risk and the need for One‑Health surveillance. Multiple U.S. commercial poultry farms were reported infected (Pennsylvania, South Dakota, Indiana, South Carolina, etc.), and wildlife/mammal infections (mountain lion, skunk) were flagged, indicating active transmission in both agricultural and wild ecosystems. International detections (Argentina, Israel, South Korea, Canada, European parks) reinforced the global, multi‑host nature of the current HPAI wave (CIDRAP elephant‑seal report; example farm reports: https://x.com/FluTrackers/status/2027040096088698925, https://x.com/FluTrackers/status/2027039675718975567).

Multistate infant botulism cluster linked to powdered infant formula

A cluster of infant botulism cases across multiple states was epidemiologically linked to ByHeart powdered infant formula and prompted a public‑health alert and formal reporting. The outbreak drew a joint public‑health response and attention in NEJM/CIDRAP alerts because of the severity and the vulnerability of the affected population (infants). This is a high‑impact product‑safety and infectious‑agent exposure event requiring product tracing, recall evaluation, and clinical vigilance (CIDRAP alert; NEJM related posting: https://x.com/NEJM/status/2026693875968954758).

Tecovirimat (Tpoxx) phase‑3 mpox trial negative

Randomized phase‑3 STOMP/A5418 trial data indicated no meaningful clinical benefit of tecovirimat over placebo for primary mpox outcomes at 29 days (clinical resolution: 83% tecovirimat vs 84% placebo). This is a major clinical‑trial signal that affects mpox treatment guidance, stockpile use, and urgency for alternative therapeutics or targeted research (NEJM trial note; CIDRAP summary).

Vaccination policy and governance — falling birth‑dose hepatitis B, litigation, and political scrutiny

Data showing a steep drop in newborn hepatitis B vaccination (from ~84% to ~73% in recent years) plus federal changes to the childhood vaccine schedule generated litigation and political response: 15 states filed suit seeking nullification of the federal schedule change. The U.S. Surgeon General nominee also faced questioning about vaccines during Senate hearings. These developments signal real policy friction at the intersection of science, law, and public trust that can directly affect outbreak trajectories and response capacity (CIDRAP vaccine coverage; legal action; hearing coverage).

Short takeaways / implications for practitioners and decision‑makers

  • Reinforce routine pediatric immunization outreach and vaccine confidence efforts immediately — falling coverage is already producing measurable outbreaks and economic burden.
  • Maintain and expand One‑Health surveillance for HPAI: animal infections in unexpected hosts (marine mammals, carnivores) and repeated commercial‑farm detections increase spillover risk and complicate control.
  • Clinicians should be aware of the infant botulism cluster and the implicated powdered formula supply; report suspect cases promptly and follow product‑safety guidance.
  • Regulatory and clinical communities should reassess mpox therapeutic strategies in light of negative tecovirimat trial results and prioritize alternative therapies and trials.
  • Address governance gaps in preparedness funding oversight to ensure funds effectively support cross‑sector readiness.

Selected source links (representative tweets cited above)

If you’d like, I can convert this into a one‑page situational brief (single page PDF or HTML) formatted for operational use, or produce a prioritized list of actions for public‑health officials and hospital infection‑control teams.